NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model

被引:4
作者
Liu, Hui [1 ,2 ]
Yu, Jian [2 ]
Chen, Xiangzhi [2 ]
Zhang, Lin [1 ,2 ]
机构
[1] China Univ Min & Technol, Engn Res Ctr Intelligent Control Underground Space, Minist Educ, Xuzhou 221116, Peoples R China
[2] China Univ Min & Technol, Sch Informat & Control Engn, Xuzhou 221116, Peoples R China
关键词
Neural matrix factorization; drug response prediction; neural networks; precision medicine; Genomics of Drug Sensitivity in Cancer (GDSC); Cancer Cell Line Encyclopedia (CCLE); KINASE INHIBITOR; CANCER; DISCOVERY; NETWORKS; PATHWAY; SENSITIVITY; COMPLETION; ANTITUMOR; GROWTH;
D O I
10.2174/1574893617666220609114052
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Anti-cancer drug response is urgently required for individualized therapy. Measurements with wet experiments are costly and time-consuming. Artificial intelligence-based models are currently available for predicting drug response but still have challenges in prediction accuracy. Objective: Construct a model to predict drug response values for unknown cell lines and analyze drug potential association properties in sparse data. Methods: Propose a Neural Matrix Factorization (NeuMF) framework to help predict the unknown responses of cell lines to drugs. The model uses a deep neural network to figure out drug and cell lines' latent variables. In NeuMF, the inputs and the parameters of the multi-layer neural network are simultaneously optimized by gradient descent to minimize the reconstruction errors between the predicted and natural values of the observed entries. Then the unknown entries can be readily recovered by propagating the latent variables to the output layer. Results: Experiments on the Cancer Cell Line Encyclopedia (CCLE) dataset and Genomics of Drug Sensitivity in Cancer (GDSC) dataset compare NeuMF with the other three state-of-the-art methods. NeuMF reduces constructing drug or cell line similarity and mines the response matrix itself for correlations in the network, avoiding the inclusion of redundant noise. NeuMF obtained drug averaged PCC_sr of 0.83 and 0.84 on both datasets. It demonstrates that NeuMF substantially improves the prediction. Some essential parameters in NeuMF, such as the global effect removal strategy and the input layer scales, are also discussed. Finally, case studies have shown that NeuMF can better learn the latent characteristics of drugs, e.g., Irinotecan and Topotecan are found to act on the same pathway TOP1. The conclusions are in line with some existing biological findings. Conclusion: NeuMF achieves better prediction accuracy than existing models, and its output is biologically interpretable. NeuMF also helps analyze the correlations between drugs.
引用
收藏
页码:835 / 847
页数:13
相关论文
共 44 条
[31]   Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines [J].
Pavillard, V ;
Agostini, C ;
Richard, S ;
Charasson, V ;
Montaudon, D ;
Robert, J .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (04) :329-335
[32]   The Raf/MEK/ERK pathway:: new concepts of activation [J].
Peyssonnaux, C ;
Eychène, A .
BIOLOGY OF THE CELL, 2001, 93 (1-2) :53-62
[33]   Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods [J].
Pouryahya, Maryam ;
Oh, Jung Hun ;
Mathews, James C. ;
Belkhatir, Zehor ;
Moosmueller, Caroline ;
Deasy, Joseph O. ;
Tannenbaum, Allen R. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[34]  
Rusnak DW, 2001, MOL CANCER THER, V1, P85
[35]   Deep learning in neural networks: An overview [J].
Schmidhuber, Juergen .
NEURAL NETWORKS, 2015, 61 :85-117
[36]   MOLI: multi-omics late integration with deep neural networks for drug response prediction [J].
Sharifi-Noghabi, Hossein ;
Zolotareva, Olga ;
Collins, Colin C. ;
Ester, Martin .
BIOINFORMATICS, 2019, 35 (14) :I501-I509
[37]   Predicting Cancer Drug Response using a Recommender System [J].
Suphavilai, Chayaporn ;
Bertrand, Denis ;
Nagarajan, Niranjan .
BIOINFORMATICS, 2018, 34 (22) :3907-3914
[38]   A generalization of the Wilcoxon signed-rank test and its applications [J].
Taheri, S. M. ;
Hesamian, G. .
STATISTICAL PAPERS, 2013, 54 (02) :457-470
[39]   Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency [J].
Takeda, Hiromasa ;
Takigawa, Nagio ;
Ohashi, Kadoaki ;
Minami, Daisuke ;
Kataoka, Itaru ;
Ichihara, Eiki ;
Ochi, Nobuaki ;
Tanimoto, Mitsune ;
Kiura, Katsuyuki .
EXPERIMENTAL CELL RESEARCH, 2013, 319 (04) :417-423
[40]  
Vougas K., 2017, BIORXIV